STOCK TITAN

From the Margins: Gilead’s Book Uniquely Captures What It’s Like To Be Marginalized by Disease

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Gilead Sciences released a new book called 'From the Margins' featuring the personal journeys of six people in the UK living with HIV, hepatitis C, and cancer. The book aims to raise awareness about the challenges faced due to stigma and health inequities. Each person's experience is deliberately written around the margins of the book to depict what it feels like to live on the periphery of society with a chronic or life-threatening disease.
Positive
  • None.
Negative
  • None.

NORTHAMPTON, MA / ACCESSWIRE / January 30, 2024 / Gilead Sciences - The personal journeys of six people in the United Kingdom living with HIV, hepatitis C and cancer - and the challenges they face due to stigma and health inequities - come together in the form of a new, intentionally difficult-to-read book from Gilead. Entitled "From the Margins," each person's experience is deliberately written around the margins of the book in order to raise awareness of what it feels like to live on the periphery of society with a chronic or life-threatening disease.

"I had one foot in my cancer patient space and the other in my LGBTQ+ space," reads an excerpt from one of the participants, named Stewart. "But there was no space where I could talk about both those things and bring them close to each other."

Gilead teamed up with David Olusoga, a British historian and professor, to put the book together. "Throughout history and to this day, there are many people pushed to the margins of society where illness intertwines with social class, race, ethnicity, sexuality and poverty," he says. "They shouldn't have to take it upon themselves to overcome societies prejudices and inequalities."

The book was published last September, and its unique format and important messages have earned significant media coverage and interest among the global patient and medical community.

The work is part of Gilead's larger efforts to spotlight and address stigma, discrimination and other barriers to wellbeing and care; and ultimately, to improve health equity.

To read From the Margins, download a copy here.

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com

SOURCE: Gilead Sciences



View the original press release on accesswire.com

FAQ

What is the title of Gilead Sciences' new book?

The title of the new book is 'From the Margins'.

What is the book about?

The book features the personal journeys of six people in the UK living with HIV, hepatitis C, and cancer, aiming to raise awareness about the challenges faced due to stigma and health inequities.

Why is the book intentionally difficult to read?

The book is intentionally difficult to read as each person's experience is deliberately written around the margins to depict what it feels like to live on the periphery of society with a chronic or life-threatening disease.

Who is one of the participants mentioned in the book?

One of the participants mentioned in the book is named Stewart, who shared his experience of having one foot in his cancer patient space and the other in his LGBTQ+ space.

What is the purpose of the book?

The purpose of the book is to raise awareness about the challenges faced by individuals living with chronic or life-threatening diseases due to stigma and health inequities.

Gilead Sciences Inc

NASDAQ:GILD

GILD Rankings

GILD Latest News

GILD Stock Data

80.78B
1.24B
0.09%
88.37%
1.81%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
FOSTER CITY

About GILD

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.